Discussion
14Sun Pharma–Organon: An Indian Giant’s $11.75 Billion Global Power Move.
Deep
an investor in Mumbai · (22 hours ago)
- India's largest overseas pharma acquisition: The announced deal is a landmark cross-border transaction for an Indian pharmaceutical company.
- A stronger global presence: The combined business is expected to generate approximately $12.4 billion in annual revenue, according to the companies' announcement.
- A major push into women's health: Organon's portfolio strengthens Sun Pharma's presence in women's healthcare, alongside general medicines and biosimilars.
- A bigger biosimilars platform: The companies projected that the combined business would become the world's seventh-largest biosimilar player.
- A global footprint: Organon has more than 70 products commercialised across 140 countries and six manufacturing facilities.
0 comments
More like this
Discussion
“𝐅𝐢𝐧𝐠𝐞𝐫-𝐋𝐢𝐜𝐤𝐢𝐧’ 𝐂𝐨𝐧𝐬𝐨𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐝𝐢𝐚’𝐬 𝐐𝐒𝐑 𝐆𝐢𝐚𝐧𝐭𝐬 𝐂𝐨𝐦𝐞 𝐔𝐧𝐝𝐞𝐫 𝐎𝐧𝐞 𝐑𝐨𝐨𝐟.”
Sapphire Foods and Devyani International have announced a landmark merger, creating one of India’s largest QSR platforms under the Yum! Brands ecosystem. Deal Structure: Share-swap merger Swap Ratio: 177 Devyani shares for every 100 Sapphire shares Scale: 3,000+ restaurants across India & international markets Synergies: ₹210–225 Cr expected annually This isn’t just about size — it’s about efficiency, bargaining power, and operating leverage in a sector facing margin pressure and slowing discretionary demand.
Deep, an investor in Mumbai
0 likes 0 comments 1 views